Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Free Report) has received an average recommendation of “Moderate Buy” from the nine analysts that are presently covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $10.78.
MRVI has been the subject of a number of research reports. Morgan Stanley cut shares of Maravai LifeSciences from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $11.00 to $10.00 in a research report on Tuesday, August 13th. UBS Group boosted their price target on shares of Maravai LifeSciences from $8.50 to $11.00 and gave the company a “neutral” rating in a research report on Thursday, August 8th. The Goldman Sachs Group boosted their price target on shares of Maravai LifeSciences from $7.00 to $8.00 and gave the company a “neutral” rating in a research report on Thursday, August 8th. Wells Fargo & Company initiated coverage on shares of Maravai LifeSciences in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $10.00 price target for the company. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $15.00 price target on shares of Maravai LifeSciences in a research report on Friday, August 16th.
Get Our Latest Stock Report on Maravai LifeSciences
Institutional Inflows and Outflows
Maravai LifeSciences Price Performance
Maravai LifeSciences stock opened at $8.61 on Friday. The stock has a market cap of $2.17 billion, a P/E ratio of -8.70 and a beta of 0.01. The company has a fifty day simple moving average of $8.77 and a 200-day simple moving average of $8.52. Maravai LifeSciences has a 12-month low of $4.52 and a 12-month high of $11.56. The company has a current ratio of 10.00, a quick ratio of 9.28 and a debt-to-equity ratio of 0.71.
Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.08) earnings per share (EPS) for the quarter. Maravai LifeSciences had a negative return on equity of 4.78% and a negative net margin of 47.41%. The firm had revenue of $73.40 million for the quarter, compared to analysts’ expectations of $71.64 million. During the same period last year, the firm posted ($0.06) earnings per share. Maravai LifeSciences’s revenue for the quarter was up 6.5% on a year-over-year basis. Equities analysts expect that Maravai LifeSciences will post -0.17 EPS for the current fiscal year.
About Maravai LifeSciences
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Recommended Stories
- Five stocks we like better than Maravai LifeSciences
- Options Trading – Understanding Strike Price
- 3 Leveraged ETFs to Multiply Returns
- What is the Nikkei 225 index?
- A Tale of Two Titans: Unveiling the Value in Baidu and JD.com
- High Flyers: 3 Natural Gas Stocks for March 2022
- Is the AI-Capable iPhone 16 the Start of a Sales Super-Cycle?
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.